Research output

Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

  • Willemsen, A. E. C. A. B.
  • de Geus-Oei, L.
  • de Boer, M.

  • Tol, J.
  • Kamm, Y.
  • de Jong, P. C.
  • Jonker, M. A.
  • Vos, A. H.
  • Grootjans, W.
  • de Groot, J. W. B.
  • Mulder, S. F.
  • Aarntzen, E. H. J. G.
  • Gerritsen, W. R.
  • van Herpen, C. M. L.
  • van Erp, N. P.

Associated organisations

    Research areas

  • MTOR INHIBITOR EVEROLIMUS, SOLID TUMORS, PHASE-I, ENDOCRINE MONOTHERAPY, MAMMALIAN TARGET, PLUS EXEMESTANE, EFFICACY, SAFETY, PET, CHEMOTHERAPY
View graph of relations

Details

Original languageEnglish
Pages (from-to)641-648
Number of pages8
JournalTargeted Oncology
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 2018